



NEWS RELEASE

FOR IMMEDIATE RELEASE

DiaSorin Molecular Introduces Primer Pair for *Candida auris*

Cypress, Calif. (November 12, 2019) – DiaSorin Molecular LLC announced today that it has released a new primer pair for use in laboratory-developed molecular tests that targets the yeast *Candida auris*. The company is a leader in the development and manufacture of primer pairs with a menu of more than 65 products for bacterial, viral and fungal targets, as well as human genetic mutations. The primer pairs are classified as Analyte Specific Reagents (ASRs), which can be used by high-complexity laboratories to develop their own laboratory developed tests (LDTs).

C. auris, according to the CDC, is a quickly emerging drug-resistant yeast that spreads in healthcare facilities and is a serious global health threat. It is often difficult to identify with non-molecular methods, with misidentification leading to poor and costly patient management. The yeast is often multi-drug resistant and has caused recent outbreaks in hospitals and long-term care facilities across the U.S and in more than 20 countries. Since the organism is becoming more common, effective and timely identification of the organism is required for mitigation of this threat.

"We are proud to offer the first commercially available molecular ASR targeting *Candida auris*," said Michelle Tabb, chief scientific officer for DiaSorin Molecular. "DiaSorin strives to listen and respond to customers regarding their needs for molecular infectious disease products."

About DiaSorin Molecular

DiaSorin Molecular LLC manufactures and distributes innovative molecular diagnostic products for hospital and reference laboratories. The company's products help laboratories consolidate their testing, streamline processes, and increase efficiency.

DiaSorin Molecular's Simplexa™ molecular diagnostic kits are designed for use on the company's versatile LIAISON® MDX platform. The company provides service and support solutions for its kits and instruments through a global network of offices and distributors. DiaSorin Molecular also markets a range of ASRs (Analyte Specific Reagents) for use in laboratory developed tests.

#

Contacts for the media

Mona Gross, Director of Market Development
DiaSorin Molecular LLC
562-240-6146
mona.gross@diasorin.com